본문으로 건너뛰기
← 뒤로

[Glutathione-responsive AP site captor Probe-NEt for anaplastic thyroid cancer: in vitro and in vivo experimental studies].

1/5 보강
Zhonghua zhong liu za zhi [Chinese journal of oncology] 📖 저널 OA 0% 2022: 0/1 OA 2023: 0/1 OA 2024: 0/11 OA 2025: 0/30 OA 2026: 0/15 OA 2022~2026 2026 Vol.48(3) p. 426-436
Retraction 확인
출처

PICO 자동 추출 (휴리스틱, conf 2/4)

유사 논문
P · Population 대상 환자/모집단
추출되지 않음
I · Intervention 중재 / 시술
low (0
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
Immunohistochemistry revealed upregulated pro-apoptotic proteins, downregulated anti-apoptotic proteins, and decreased Ki-67 expression. The glutathione-responsive AP site captor Probe-NEt significantly inhibits ATC cell growth, induces G/M phase cell cycle arrest, promotes late apoptosis, and exhibits high selectivity and favorable biosafety profiles.

Su MX, Chai JY, Zhang RG, Sun DY, Zheng W, Li N

📝 환자 설명용 한 줄

To exploit the elevated glutathione (GSH) levels in the tumor microenvironment and investigate the therapeutic efficacy of a novel glutathione-responsive apurinic/apyrimidinic (AP) site captor, Probe-

이 논문을 인용하기

↓ .bib ↓ .ris
APA Su MX, Chai JY, et al. (2026). [Glutathione-responsive AP site captor Probe-NEt for anaplastic thyroid cancer: in vitro and in vivo experimental studies].. Zhonghua zhong liu za zhi [Chinese journal of oncology], 48(3), 426-436. https://doi.org/10.3760/cma.j.cn112152-20250608-00265
MLA Su MX, et al.. "[Glutathione-responsive AP site captor Probe-NEt for anaplastic thyroid cancer: in vitro and in vivo experimental studies].." Zhonghua zhong liu za zhi [Chinese journal of oncology], vol. 48, no. 3, 2026, pp. 426-436.
PMID 41876200 ↗

Abstract

To exploit the elevated glutathione (GSH) levels in the tumor microenvironment and investigate the therapeutic efficacy of a novel glutathione-responsive apurinic/apyrimidinic (AP) site captor, Probe-NEt, against anaplastic thyroid cancer (ATC). Fluorescence imaging compared Probe-NEt uptake and activation in normal thyroid (Nthy ori 3-1), ATC (THJ-16T, CAL-62), and lung cancer (H1299) cells. Half maximal inhibitory concentration (IC) values were determined by cytotoxicity assays; DNA damage was evaluated using appropriate assays. Flow cytometry analyzed cell cycle distribution and apoptosis following treatment with low (5 μmol/L) or high (20 μmol/L) Probe-NEt concentrations. BALB/c nude mice bearing subcutaneous ATC xenografts received low (0.025 mg) or high (0.05 mg) dose injections. Tumor volumes were monitored; HE staining assessed biosafety in major organs; immunohistochemistry detected apoptosis-related protein expression. ATC cells demonstrated significantly higher Probe-NEt activation than normal thyroid cells. Probe-NEt exhibited selective cytotoxicity (higher IC in normal vs. ATC cells; all <0.01) with time-dependent characteristics; the selectivity ratio increased from 1.7 at 24 h (62.4 vs. 37.7 μmol/L) to 2.4 at 48 h (32.7 vs. 13.5 μmol/L). Probe-NEt induced DNA damage, G/M arrest (THJ-16T: from 5% to 43%; CAL-62: from 19% to 37%), and dose-dependent late apoptosis. In THJ-16T cells, late apoptotic rates rose from 5.49% (control) to 13.95% (low-dose) and 63.43% (high-dose), with viable cells decreasing accordingly (89.42%, 76.01%, 20.45%). CAL-62 cells showed similar trends (16.72%, 40.19%, 69.88%). , Probe-NEt significantly suppressed tumor growth without hepatorenal toxicity (all >0.167). Immunohistochemistry revealed upregulated pro-apoptotic proteins, downregulated anti-apoptotic proteins, and decreased Ki-67 expression. The glutathione-responsive AP site captor Probe-NEt significantly inhibits ATC cell growth, induces G/M phase cell cycle arrest, promotes late apoptosis, and exhibits high selectivity and favorable biosafety profiles.

🏷️ 키워드 / MeSH 📖 같은 키워드 OA만

🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반